-
公开(公告)号：US20230158009A1
公开(公告)日：2023-05-25
申请号：US18101499
申请日：2023-01-25
申请人： Celgene Corporation
发明人： Soraya Carrancio , Paul Hollenbach , Antonia Lopez-Girona , Kyle MacBeth , Michael Pourdehnad , Irit Rappley , Gang Lu
IPC分类号： A61K31/454 , A61K9/00 , A61K9/19
CPC分类号： A61K31/454 , A61K9/0019 , A61K9/19
摘要： Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.
-
公开(公告)号：US20210154182A1
公开(公告)日：2021-05-27
申请号：US16920267
申请日：2020-07-02
申请人： Celgene Corporation
发明人： Soraya Carrancio , Paul Hollenbach , Antonia Lopez-Girona , Kyle MacBeth , Michael Pourdehnad , Irit Rappley , Gang Lu
IPC分类号： A61K31/454 , A61K9/00 , A61K9/19
摘要： Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.
-
3.发明申请公开(公告)号：US20200377512A1
公开(公告)日：2020-12-03
申请号：US16887766
申请日：2020-05-29
申请人： Celgene Corporation
发明人： Frans Baculi , Katherine Northcote , Matthew D. Correa , Joshua Hansen , Laurie A. Lebrun , Chin-Chun Lu , Gang Lu , Mark A. Nagy , Sophie Peng , Sophie Perrin-Ninkovic
IPC分类号： C07D491/107 , C07D401/04 , C07D401/14 , C07D405/14 , C07D413/14 , A61P35/02
摘要： Provided herein are 1-oxo-isoindoline-5-carboxamide compounds having the following structure: wherein R1, R2, R3, R4 and n are as defined herein, compositions comprising an effective amount of a 1-oxo-isoindoline-5-carboxamide compound, and methods for treating or preventing disorders.
-
公开(公告)号：US10830762B2
公开(公告)日：2020-11-10
申请号：US16066288
申请日：2016-12-27
申请人： Celgene Corporation
IPC分类号： A61K38/00 , G01N33/50 , G16B30/00 , G01N33/566 , C07D401/04 , A61K31/4035 , C07K14/47 , C12N15/62 , G01N33/573 , A61K38/18
摘要： Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
-
公开(公告)号：US10245258B2
公开(公告)日：2019-04-02
申请号：US15614434
申请日：2017-06-05
申请人： Celgene Corporation
发明人： Soraya Carrancio , Paul Hollenbach , Antonia Lopez-Girona , Kyle MacBeth , Michael Pourdehnad , Irit Rappley , Gang Lu
IPC分类号： A61K31/454 , A61K9/19 , A61K9/00
摘要： Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.
-
6.发明申请公开(公告)号：US20190017998A1
公开(公告)日：2019-01-17
申请号：US16066288
申请日：2016-12-27
申请人： Celgene Corporation
IPC分类号： G01N33/50 , C12N15/62 , C07K14/47 , G01N33/573 , A61K31/4035 , G06F19/22
CPC分类号： G01N33/5008 , A61K31/4035 , A61K38/00 , A61K38/18 , C07D401/04 , C07K14/4702 , C07K2319/95 , C12N15/62 , C12Y203/02 , G01N33/566 , G01N33/573 , G16B30/00
摘要： Provided herein are compositions, therapeutic methods, screening methods, computational methods and biomarkers based upon the elucidation of the interaction among cereblon, its substrates and certain compounds or agents, including small molecules, peptides, and proteins.
-
公开(公告)号：US20230341375A1
公开(公告)日：2023-10-26
申请号：US18216405
申请日：2023-06-29
申请人： Celgene Corporation
发明人： Maria Soraya Carrancio Anton , Joshua Hansen , Courtney G. Havens , Antonia Lopez-Girona, SR. , Gang Lu , Daniel W. Pierce , Lilly L. Wong
IPC分类号： G01N33/50 , G01N33/68 , G01N33/574 , A61K31/496 , A61P35/02
CPC分类号： G01N33/5011 , G01N33/6869 , G01N33/57484 , A61K31/496 , G01N33/6866 , A61P35/02 , G01N2800/52 , A61K45/06
摘要： A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.
-
公开(公告)号：US11590117B2
公开(公告)日：2023-02-28
申请号：US16920267
申请日：2020-07-02
申请人： Celgene Corporation
发明人： Soraya Carrancio , Paul Hollenbach , Antonia Lopez-Girona , Kyle MacBeth , Michael Pourdehnad , Irit Rappley , Gang Lu
IPC分类号： A61K31/454 , A61K9/00 , A61K9/19
摘要： Provided herein are methods of treating, preventing, managing, and/or ameliorating leukemia or myelodysplastic syndrome comprising administering 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide or a stereoisomer or mixture of stereoisomers, an isotopologue, pharmaceutically acceptable salt, tautomer, solvate, hydrate, co-crystal, clathrate, or polymorph thereof to a patient.
-
公开(公告)号：US20220213115A1
公开(公告)日：2022-07-07
申请号：US17690921
申请日：2022-03-09
申请人： Celgene Corporation
发明人： Frans Baculi , Katherine Northcote , Matthew D. Correa , Joshua Hansen , Laurie A. Lebrun , Chin-Chun Lu , Gang Lu , Mark A. Nagy , Sophie Peng , Sophie Perrin-Ninkovic
IPC分类号： C07D491/107 , C07D401/04 , A61P35/02 , C07D405/14 , C07D413/14 , C07D401/14
摘要： Provided herein are 1-oxo-isoindoline-5-carboxamide compounds having the following structure: wherein R1, R2, R3, R4 and n are as defined herein, compositions comprising an effective amount of a 1-oxo-isoindoline-5-carboxamide compound, and methods for treating or preventing disorders.
-
公开(公告)号：US20210181184A1
公开(公告)日：2021-06-17
申请号：US17173176
申请日：2021-02-10
申请人： Celgene Corporation
发明人： Maria Soraya Carrancio Anton , Joshua Hansen , Courtney G. Havens , Antonia Lopez-Girona , Gang Lu , Daniel W. Pierce , Lilly L. Wong
IPC分类号： G01N33/50 , G01N33/68 , G01N33/574 , A61K31/496
摘要： A method of identifying a subject having cancer who is likely to be responsive to a treatment compound, comprising administering the treatment compound to the subject having the cancer; obtaining a sample from the subject; determining the level of a biomarker in the sample from the subject; and diagnosing the subject as being likely to be responsive to the treatment compound if the level of the biomarker in the sample of the subject changes as compared to a reference level of the biomarker; wherein the treatment compound is Compound 1, Compound 2, or Compound 3.
-
-
-
-
-
-
-
-
-
搜索结果
20 条记录 (耗时 0.021 秒)
